Objective. To assess the possibility of using the cellular composition, concentration of C-reactive protein (CRP) and albumin in blood of patients with early stages of non-small cell lung cancer (NSCLC) for determination of a risk of tumor progression at the pretreatment period.

Material and methods. In 103 NSCLC patients the blood cell concentration was determined in whole blood and CRP and albumin concentration — in blood serum. All patients were divided for further analysis on groups of low (I stage G1, G2, II stage G1 — 57 patients) and high risk of relapse of NCCLC (I stage G3, II stage G2, G3 — 46 patients).

Results. The ratio of the concentration of lymphocytes to the concentration of monocytes was significantly lower, and the concentration of albumin and the ratio of the level of albumin to the level of CRP were significantly higher in the high-risk group. The diagnostic efficiency (DE) of their measurement for the calculated threshold values in order to predict the probability of progression ranged between 62.1% for albumin and 65% for the lymphocyte/monocyte ratio. To increase the predictive value two mathematical models were built in the form of logistic equations. The 1-st model includes the ratio of lymphocytes/monocytes and CRP/albumin: the threshold value is 0.403; sensitivity — 67.4%, specificity — 78.9, DE — 73.8%. 2-nd model includes the same indicators, the level of CYFRA 21-1 and receptors CXCR1, CXCR2, CD44v6, previously substantiated by us as promising for predicting tumor progression on early stages of NSCLC; the obtained threshold value is 0.507, sensitivity — 87.0%, specificity — 91.2, DE — 89.3%.

Conclusion. The risk of progression of NSCLC can be predicted with a high degree of reliability in patients with early stages of NSCLC using a complex of routine blood parameters and protein biomarkers — metabolites of the developing tumor.